Alzheimer's Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
After adjusting for a large set of confounders, including the use of anti-inflammatory drugs, only higher LBP levels were significantly associated with a 30% higher odds of developing AD over 12 years (OR 1.30, 95% CIs [1.07-1.59]), regardless of IL6 levels.
|
31450497 |
2019 |
Alzheimer's Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
The model we have hypothesized for Alzheimer's disease involves damage signals that promote glial activation, followed by nuclear factor NF-kβ activation, synthesis, and release of proinflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, IL-6, and IL-12 that affect neuronal receptors with an overactivation of protein kinases.
|
31572186 |
2019 |
Alzheimer's Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
A total of 170 studies were included in the meta-analysis and systematic review, which demonstrated increased peripheral levels of high-sensitivity C reactive protein (Hedges's g 0.281, p<0.05), interleukin-6 (IL-6) (0.429, p<0.005), soluble tumour necrosis factor receptor 1 (sTNFR1) (0.763, p<0.05), soluble tumour necrosis factor receptor 2 (sTNFR2) (0.354, p<0.005), alpha1-antichymotrypsin (α1-ACT) (1.217, p<0.005), IL-1β (0.615, p<0.05) and soluble CD40 ligand (0.868, p<0.005), and CSF levels of IL-10 (0.434, p<0.05), monocyte chemoattractant protein-1 (MCP-1) (0.798, p<0.005), transforming growth factor-beta 1 (1.009, p<0.05), soluble triggering receptor expressed on myeloid cells2 (sTREM2) (0.587, p<0.001), YKL-40 (0.849, p<0.001), α1-ACT (0.638, p<0.001), nerve growth factor (5.475, p<0.005) and visinin-like protein-1 (VILIP-1) (0.677, p<0.005), in AD compared with the control.
|
30630955 |
2019 |
Alzheimer's Disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
QC activity, the formation of pE-Aβ and Aβ plaques and the activation of astrocytes and microglia cells in AD mice brains were inhibited, and the levels of inflammatory factors such as IL-6, IL-1β and TNF-α in serum were reduced remarkably.
|
31377588 |
2019 |
Alzheimer's Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
The Synthetic Retinoid Acitretin Increases IL-6 in the Central Nervous System of Alzheimer Disease Model Mice and Human Patients.
|
31396076 |
2019 |
Alzheimer's Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
In this study, we analyzed the role of IL-6 trans-signaling in two mouse models of AD, Tg2576 and 3xTg-AD mice.
|
31401302 |
2019 |
Alzheimer's Disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The aim of our study was to assay circulating interleukin-15 (IL-15) and interleukin-6 (IL-6) levels and insulin resistance measured by two different methods in newly diagnosed autoimmune diabetes (AD) patients, their I° relatives, and healthy controls.
|
31772933 |
2019 |
Alzheimer's Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Humanin is a novel neuronal peptide that has displayed potential in the treatment of Alzheimer's Disease through the suppression of inflammatory IL-6 cytokine receptors.
|
30381074 |
2019 |
Alzheimer's Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
By virological and molecular analyses we found: i) HSV-1 spreading and replication in different brain regions after thermal stress-induced virus reactivations; ii) accumulation of AD hallmarks including amyloid-β protein, tau hyperphosphorylation, and neuroinflammation markers (astrogliosis, IL-1β and IL-6).
|
30870531 |
2019 |
Alzheimer's Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Our data showed that SEO improved the cognitive ability of mice with Aβ<sub>1-42</sub> or lipopolysaccharides (LPS)-induced Alzheimer's disease (AD) and suppressed the production of tumor necrosis factor-a (TNF-a), interleukin-6 (IL-6), and interleukin-1β (IL-1β) in the hippocampus.
|
31463498 |
2019 |
Alzheimer's Disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
In the AD model group, the inhibition of PC12 cell growth was significantly increased, and the mRNA expression levels of IL‑1β, IL‑6, TNF‑α and MIF were also increased.
|
31322215 |
2019 |
Alzheimer's Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
There were (i) direct correlations between polymorphonuclear cells in the bronchoalveolar fluid and cerebral soluble amyloid-β<sub>1-40</sub> (p = 0.0033), and several Alzheimer's disease-relevant neuroinflammatory biomarkers including cerebral TNF-α and IL-6; (iii) significant decreases in blood-brain barrier permeability in mechanically ventilated Alzheimer's disease mice and a trend towards increased blood-brain barrier permeability in mechanically ventilated wild-type mice.
|
30795776 |
2019 |
Alzheimer's Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Similarly, elevated serum amyloid β (Aβ) 42, cholesterol, oxidative stress markers, IL-6, heat shock protein (HSP) 90, caspase-3, and p-tau, as well as increased expression of tau, MAPK1 and PTEN in AD patients, were significantly reduced upon LF intake.
|
30611996 |
2019 |
Alzheimer's Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Increased inflammatory cytokines, such as interleukin-6 (IL-6), interleukin-1β (IL-1 β), and tumor necrosis factor-α (TNF-α) are associated with Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), and multiple sclerosis (MS).
|
28856541 |
2018 |
Alzheimer's Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Elderly with depression have higher IL-6 than controls, while those with Alzheimer's disease did not have higher peripheral inflammatory markers.
|
30104698 |
2018 |
Alzheimer's Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
In AD dementia, MDSC populations are reduced with decreased suppression of monocyte IL-6 (5.22%) and T cell proliferation (37.61%); the reduced suppression coincides with increased pro-inflammatory signaling in AD dementia monocytes.
|
30424785 |
2018 |
Alzheimer's Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Alterations in extracellular matrix proteins in addition to increasing amount of hippocampal IL6 and iron in the early stages of AD may reveal inflammation-mediated iron dyshomeostasis in the early stages of neurodegeneration.
|
29376847 |
2018 |
Alzheimer's Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
C-reactive protein (HR = 1.37 [1.05; 1.78]), interleukin-6 (HR = 1.40 [1.13; 1.73]), α1-antichymotrypsin (HR = 1.54 [1.14; 2.80]), lipoprotein-associated phospholipase A2 activity (HR = 1.40 [1.03; 1.90]), and fibrinogen were each associated with all-cause dementia, but neither was significantly associated with AD.
|
29605221 |
2018 |
Alzheimer's Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Furthermore, the concentrations of interleukin‑6 (IL‑6) and tumor necrosis factor‑α (TNF‑α) were tested for in the brain tissues of AD mice.
|
29568861 |
2018 |
Alzheimer's Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
After nine months of treatment in APP/PS1 double-transgenic mice, scutellarin significantly improves behavior, reduces soluble and insoluble Aβ levels in the brain and plasma, decreases Aβ plaque associated gliosis and levels of proinflammatory cytokines TNF-α and IL-6, attenuates neuroinflammation, displays anti-amyloidogenic effects, and highlights the beneficial effects of intervention on development or progression of AD-like neuropathology.
|
29642616 |
2018 |
Alzheimer's Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
This study investigates peripheral proinflammatory cytokines (interferon gamma [IFN-γ], tumor necrosis factor alpha [TNF-α], and interleukins 1β [IL-1β] and 6 [IL-6]) by firstly comparing peripheral blood mononuclear cell (PBMC)-derived secretion in drug-naïve and AChEI-treated AD patients versus healthy controls.
|
29420357 |
2018 |
Alzheimer's Disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
In Alzheimer's disease, the synaptic proteins synaptophysin and PSD-95 were quantified by ELISA, and the inflammatory proteins and mRNAs by MesoScale Discovery Multiplex Assays and qPCR, respectively.Systemic infection in Alzheimer's disease was associated with decreased CD16 (p = 0.027, grey matter) and CD68 (p = 0.015, white matter); increased CD64 (p = 0.017, white matter) as well as increased protein expression of IL6 (p = 0.047) and decreased IL5 (p = 0.007), IL7 (p = 0.002), IL12/IL23p40 (p = 0.001), IL15 (p = 0.008), IL16 (p < 0.001) and IL17A (p < 0.001).
|
30193587 |
2018 |
Alzheimer's Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
The proinflammatory cytokine interleukin 6 (IL-6) has been prominently associated with the pathogenesis of AD and MDD.
|
28382017 |
2017 |
Alzheimer's Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Also, correlation results of IL1 and IL6 suggest stronger inflammatory effects in LOBD than in AD.
|
28670271 |
2017 |
Alzheimer's Disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
In addition, Aβ<sub>1-42</sub> oligomers enhanced secretion of IL-1β, TNF-α, and IL-6 into culture supernatant, which may be correlated with an inflammatory response and altered EAATs expression or function in Alzheimer's disease.
|
28189841 |
2017 |